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Introduction: Depression is highly prevalent and often accompanied by comorbid
anxiety disorder. Internet-based interventions have shown to be one effective treatment
modality; however, comorbidities are often not targeted. Transdiagnostic tailored internet-
and mobile-based interventions (IMIs) might be promising to overcome such issues.
Aim: This study aims to evaluate the efficacy, moderators, and cost-effectiveness of a
transdiagnostic tailored internet- and mobile-based guided intervention for depression
and comorbid anxiety in individuals with major depressive disorder (MDD).
Method: Two-hundred participants with MDD will be randomly assigned to an
8-week guided self-help internet intervention (IC) or a 6-month wait-list control group
(WLC). Participants of the IC will receive weekly content-focused feedback on module
completion as well as monitored adherence reminders from an eCoach. The primary
outcome is clinician-rated depression severity (QIDS-C) at post-assessment assessed
by diagnostic raters blind to study condition. Secondary outcomes include, e.g., change
in diagnostic status (MDD and anxiety disorders), remission and response rates, disorder
symptom severity, health related quality of life, incongruence related to needs and values,
and behavioral activation. Assessments will take place at baseline (T1), post-assessment
(T2), 6-month follow-up (T3), and 12-month follow-up in the IC. Data will be analyzed on
an intention-to-treat basis and per protocol. A large number of a priori definedmoderators
of treatment outcome will be assessed at baseline and tested in predicting treatment
outcome. Cost-effectiveness will be evaluated from a societal perspective.
Discussion: The present study will provide evidence on the efficacy, potential
cost-effectiveness, and moderators of a transdiagnostic tailored guided internet- and
mobile-based treatment protocol.
Trial Registration: German Register of Clinical Studies DRKS00011690 (https://www.
drks.de/drks_web/).
Keywords: depression, anxiety, comorbidity, transdiagnostic, tailored, internet intervention, randomized
controlled trial, guided self-help
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INTRODUCTION
Depression is one of the most prevalent common mental
disorders (CMDs) worldwide (1, 2), with a range of adverse
personal and societal consequences (3–5). Prevalence rates of
major depressive disorder (MDD) in the US and Germany
are estimated at ∼19% for lifetime prevalence and range from
6% to 12% for 12-month prevalence (1, 2, 6). Reducing the
prevalence rates and disease burden is an important issue
from a public health perspective (6). Depressive disorder is
associated with negative physical and mental health outcomes
such as reduced quality of life, suicide ideation, chronic medical
conditions, disability, noncompliance with medical treatment,
and heightened mortality risk (7–13).
Individuals suffering from MDD have an increased likelihood
of comorbidity such as suffering from another CMD (14–16).
Comorbidity is estimated to range from 40% to 80% in both
clinical and epidemiological studies (14, 17). Individuals suffering
from MDD often also suffer from anxiety disorder (AD) as
found in an epidemiological study with an estimate of 53% (18).
Comorbidity negatively influences daily functioning, is linked to
greater severity and chronicity of disorder course, and associated
with higher mortality in medical conditions such as heart disease
(8, 19).
Even though effective treatment modalities exist for MDD
and for ADs (20–22), there is still a large unmet need for
treatment. Treatment barriers can be categorized as structural,
e.g., restricted accessibility to treatment and availability thereof,
and communities with high mental health stigma might prevent
individuals from seeking help, or individual and attitudinal
treatment barriers such as physical impairment, time constraints,
unaffordable treatment costs, preference for other types of
treatment, or preference for self-help (23, 24).
One modality of treatment delivery is through internet- and
mobile-based interventions (IMIs) which can help overcome
some traditional treatment barriers and generally facilitate
treatment utilization. Advantages include (1) anonymity, (2)
treatment flexibility, (3) low threshold access, (4) fostering self-
efficacy, (5) cost-population scalability, and (6) standardization.
A fair amount of studies have shown internet interventions
to be effective in treating symptoms of depression and
anxiety (25–28). A review examining treatment for depression
considered five studies with 429 participants comparing face-
to-face and guided internet-based CBT (iCBT) (25). Meta-
analytic summary statistics found average effect sizes Hedges’
g = 0.12 (95% CI: −0.06–0.30) in favor of guided iCBT
which indicates both type of treatments to be comparable.
Another extensive meta-analysis explored the effects of therapist-
supported iCBT compared to wait-list, unguided CBT, or
face-to-face CBT on remission of anxiety disorder diagnosis
and reduction of anxiety symptoms in adults (28). After
screening by two independent researchers, 30 studies were
included which showed iCBT to be efficacious in reducing
anxiety symptoms. Overall, meta-analytic evidence found
guided iCBT to produce comparable overall effects to face-
to-face CBT in treating depression and anxiety disorders
(28).
However, utilizing internet interventions for the treatment
of mental disorders can also pose some challenges, such
as low treatment commitment, incompatibleness of personal
characteristics and treatment modality self-help, and missing
or limited individualization options which may lead to higher
dropout rates and decreased overall efficacy (29–31). To
overcome some of these issues, their impact must be carefully
considered during the study design phase and strategies
to diminish negative effects should be incorporated, e.g.,
adherence monitoring, therapeutic contact through guidance,
and individual tailoring.
Recent systematic reviews indicate that internet-based
interventions can also be a cost-effective mean to treat depression
and anxiety, when compared to wait-list, treatment-as-usual
(TAU), or unguided iCBT (32, 33).
However, despite the high comorbidity rates of MDD and
ADs, it is currently recommended and standard procedure to
treat mental health disorders separately with disorder-specific
interventions (DSIs), e.g., through indicative CBT (34, 35). Even
though many DSIs have been developed, evaluated and shown to
be effective in randomized controlled trials (RCTs) (20–22), there
seem to be some limitations to treating disorders in isolation
without targeting comorbidity. Potential risks include that DSIs
might dismiss comorbid symptoms and comorbid conditions
could worsen, comorbidities could negatively influence treatment
response in DSIs, participants might need prolonged treatment
or several separate treatment procedures, and due to treatment
costs affected individuals might not be able to afford all the
necessary treatments (15, 19, 36, 37).
Therefore, transdiagnostic treatment concepts, treating at
least two disorders simultaneously, might help overcome some
issues of DSIs (37). Transdiagnostic interventions can be
designed in different manners by identifying and addressing
common risk factors including etiological and maintaining
factors, common underlying behavioral mechanisms of MDD
and AD, and overlapping symptom profiles (38–40).
There is meta-analytic evidence that transdiagnostic
computerized CBT programs can result in large effect sizes
for depression (g = 0.84) and medium effect sizes for
anxiety (g = 0.78) (41). Moreover, a recent meta-analysis
of transdiagnostic psychological treatments for anxiety and
depression found manualized transdiagnostic interventions,
delivered face-to-face or over the internet to be effective with
large effects for depression (g = 0.91) and anxiety (g = 0.85)
(42). However, heterogeneity was high indicating significant
differences in treatment effects across studies. More high quality
RCTs are needed to investigate the efficacy of transdiagnostic
internet-based treatment protocols.
Comparing transdiagnostic concepts to DSIs, recent meta-
analytic exploration indicates transdiagnostic internet-based
treatments could be as effective for reducing anxiety symptoms
and potentially superior in reducing symptoms of comorbid
depression compared to DSIs which focused solely on anxiety
(42, 43).
It is possible that the model “one size fits all” commonly
applied in DSIs and in manualized transdiagnostic interventions
might not be effective for all participants. A method to
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overcome limitations related to standardization is by applying
individual tailoring techniques of treatment content. In these
instances, the treatment protocol is not standardized for all
participants, but can rather be adapted individually based on
different criteria, such as participants symptom profiles, stage
of motivation, preference, needs, characteristics, or clinician
recommendation (37, 44, 45). Even in standardized face-to-
face therapy, individual tailoring can be an integral part of
the treatment expressed by, e.g., vocal inflection, personal
circumstances, type of psychoeducational model, and therapists’
work experience. These elements often cannot be translated
directly to internet interventions which is why it is important
to include other elements of individual tailoring to personalize
internet-based psychological treatment.
A meta-analysis investigated the efficacy of internet-delivered
transdiagnostic and tailored CBT for comorbid anxiety and
depression and found controlled moderate to large effects for
both depression and anxiety (anxiety: g = 0.82, 95% CI: 0.58–
1.05, depression: g = 0.79, 95% CI: 0.59–1.00) compared to
control groups which included wait-list and active wait-list
on the basis of 19 studies including 2952 participants (37).
However, there are generally few RCTs investigating the effects
of transdiagnostic treatment and individual tailoring.
Another issue which has not been explored sufficiently
to date are differential treatment effects of IMIs, e.g., who
profits from participation in such interventions and who does
not. Trials designed to investigate overall treatment effects are
generally underpowered to adequately investigate efficacy in
subgroups, as approximately four times as many participants are
needed to detect an interaction effect between a moderator and
the treatment condition compared to the primary effect (46).
Furthermore, moderation analyses are often not planned a priori
so that it is unlikely relevant moderators are additionally added
to the study assessments. However, it is important to include a
broad range of potential moderators, to power, and to test for
moderation, as identifying moderators of treatment outcome can
help better understand heterogeneity of treatment response (47).
The aim of the present study is to evaluate the efficacy,
moderators, and cost-effectiveness of a transdiagnostic individual
participant tailored internet-based mobile-supported guided
intervention for depression and anxiety in individuals withMDD
with and without comorbid anxiety.
METHODS
Design
A two-armed RCTwill be conducted to compare the intervention
condition (IC) ICare Stimmung with a wait-list control group
(WLC). Individuals assigned to the WLC will receive access to
the intervention 6months after study begin. They can contact the
study administration at any time through the messaging function
on the platform or by email. They can seek other treatment after
study uptake and they additionally receive an information sheet
detailing psychological treatment options upon high symptom
severity assessed in the diagnostic interview or upon contacting
the study administration team.
Diagnostic interviews and self-report assessments will take
place at baseline (T1), post-assessment (T2), and at 6-month
follow-up (T3) (see Figure 1 for a detailed overview). There
will also be weekly mood assessments during the first 7 weeks
of the study phase. Diagnostic interviews will be conducted
via telephone. Self-report data will be collected using a secure
online-based assessment system (AES, 256-bit encrypted). All
procedures involved in the study will be consistent with the
generally accepted standards of ethical practice. The study
was approved by the Friedrich-Alexander-Universität Erlangen-
Nürnberg ethics committee (No. 144_16B). The trial is registered
in the German Clinical Trial Registry under DRKS00011690
(https://www.drks.de/drks_web/).
Participants and Procedure
Inclusion and Exclusion Criteria
We will include (1) adults (≥18 years), (2) with a diagnosis of
MDD according to DSM-IV criteria assessed by diagnostic raters
using the Mini international neuropsychiatric interview (MINI)
(48), (3) internet access, (4) a valid email address, (5) sufficient
skills in the German language in reading and writing, and (6) who
agreed to the terms of this trial by providing signed informed
consent. Individuals are informed that they can discontinue
the study at any point without any consequences. Individuals
will be excluded who (1) have a history of manic/hypomanic
episodes, (2) or psychotic disorder, (3) are currently receiving
psychotherapy for MDD or anxiety, (4) are on a wait-list for
psychotherapeutic treatment, or (5) received treatment in the
previous 6 months, and (6) show a notable suicidal risk in the
diagnostic interview. The trial is open to all German speaking
participants residing in Germany, Switzerland, or Austria.
Recruitment
Recruitment will take place primarily over German and Swiss
health insurance companies who advertise the study on their
website and in members’ magazines. Individuals can take part
in the study no matter their insurance status or company. We
will also advertise via Facebook and targeted advertising, the
study website (www.icareprevent.com), and open recruitment
strategies, e.g., radio segments, print media, and social media.
The study website provides information on the online treatment
and study procedure. This recruitment aims to mimic a public
health approach of mental health treatment, in which access to
treatment is not limited by face-to-face gatekeepers. Recruitment
begin was May 2017. Interested individuals can sign up by
providing their email address and a name or pseudonym on the
study website or by contacting the study administration directly
via email. They are advised that they can create a new email for
study participation. Primary recruitment is for ICare Prevent, a
study on transdiagnostic prevention of depression and anxiety
for a subclinical population. Individuals who receive a diagnosis
of MDD in the screening process will be excluded from the ICare
Prevent trial and included in the present study.
Assessment of Eligibility and Randomization
Individuals interested in study participation will receive a
detailed email with information on the study procedure. The
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FIGURE 1 | Study flow.
applicants are then asked to complete an online screening
containing question on demographic information, current
state and history of mental health, and experience with
psychotherapeutic treatment. Individuals who show symptoms
of depression (CES-D ≥ 16) and do not fulfill any of the
exclusion criteria will receive detailed study information and are
requested to acknowledge and sign the consent form. The signed
consent form can be sent by postal mail or email. Following
informed consent, diagnostic interviews will be conducted by
trained diagnostic assessors. Individuals who fulfill all inclusion
criteria and no exclusion criteria proceed to complete baseline
assessments. Once these are completed, individuals are included
in the study and randomized to one of the study conditions, the
guided intervention (IC) or the wait-list control (WLC) group.
Randomization will take place at an individual level by an
independent researcher not otherwise involved in the study
administration. A randomization list is created in a 1:1 ratio
based on sequences of 8 per block using an automated
computer-based random integer generator (randlist). Until
randomization is completed, allocation will be concealed from
participants, researchers involved in study administration, and
eCoaches. eCoaches are psychologists or psychotherapists in
training, licensed psychotherapists, or trained masters’ level
psychology students providing support to the participants
during the duration of the online training. Outcome assessors
will remain blind throughout the study. After randomization,
participants will be informed of the outcome, and participants in
the IC will receive immediate access to the online treatment while
participants randomized to the WLC will receive login access to
the training 6 months after study intake.
Participant Safety
Individuals who show symptoms of heightened suicidality will be
treated according to a standardized procedure, e.g., during the
diagnostic telephone interview individuals will be excluded from
study participation and strongly advised to seek help and support
from their general practitioner or local psychiatric emergency
room. All relevant information containing emergency contact
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numbers will be additionally sent via email. This procedure
will also be followed should participants show symptoms of
suicidality throughout the study phase. Additionally, participants
already included in the study are contacted by an experienced
clinician who will determine suicidality symptom severity and
discuss next steps concerning their mental health.
Intervention Development and Content
The intervention was developed in an expert-driven manner
(49). After the initial development phase, the intervention was
tested in a small-scale alpha-testing with a group of students.
Additionally, four qualitative interviews with students who had
completed the intervention were conducted. The collected data
was used to make minor improvements and modifications to the
intervention content.
The main sessions cover the following topics: behavioral
activation: reducing incongruence, behavioral activation:
overcoming difficulties and pleasant activity scheduling,
psychoeducation on depression and anxiety, cognitive
restructuring, problem solving or exposure, and planning
for the future. Individual participant tailoring is promoted by
providing participants with frequent choices on intervention
topics and treatment preferences. In addition to transdiagnostic
elements, they can further choose to focus on depression, anxiety,
or both disorders, and work through various elective modules on
different topics: rumination and worries, acceptance, relaxation,
reducing alcohol, self-worth, perfectionism, appreciation and
gratefulness, and sleep. See Table 1 for an overview of the
sessions and elective modules.
Elective modules can freely be chosen based on participant
preference throughout the intervention. Furthermore,
participants can opt to receive tiny tasks which consist of
short motivational notifications and small transfer tasks sent
throughout each day during the intervention phase through the
app. Furthermore, the intervention strongly relies on content
tailoring which engages the participant to make real-time choices
among various response options by providing immediate content
based on participant preference or need. Participants can choose
between two versions of the tiny tasks, the light version (three
notifications per day), intensive version (five notifications per
day), or they can choose not to receive notifications. The tiny
tasks are sent through an additional app component which
participants can install on their smartphone. They can also use
the app for their diary entries.
The intervention content consists of texts, testimonials,
audios, short educational video clips, and interactive elements
such as quizzes. To foster self-efficacy and stabilize the long-term
learning process, participants are instructed from the beginning
to integrate and practice newly acquired strategies in their
daily life, e.g., through scheduling individualized weekly activity
plans, using online diaries, and receiving daily tiny tasks. At
the beginning of each session, participants review the previous
session content and evaluate how the practicing of homework
worked. Sessions are estimated at ∼60min and participants
are advised to do one session per week and a maximum of
two. Therefore, the training is supposed to last 4–7 weeks.
Responsive web-design enables the training to be completed on
TABLE 1 | ICare Stimmung training.
Sessions Elective modules
(sessions 2–7)
1 Behavioral activation: reducing incongruence
2 Behavioral activation: overcoming difficulties
and pleasant activity scheduling
Rumination & worries,
acceptance, relaxation, reducing
alcohol, self-worth,
perfectionism, appreciation and
gratefulness, sleep
3 Psychoeducation
4 Cognitive restructuring
5 Problem solving I or exposure I
6 Problem solving II or exposure II
7 Plan for the future
8 Booster session
any kind of internet-ready device. The read-aloud function allows
participants to follow the intervention also through narration.
Behavioral Activation: Reducing Incongruence
(Session 1)
Participants are introduced to core functionalities of the training
in the first session, such as testimonials, diaries, videos, and
the tiny tasks sent through the app. The first session aims at
teaching techniques to reduce incongruence between individual
perceptions and goals and thereby enhance psychological well-
being. This concept is based on the consistency theory by Grawe
(50). Participants are encouraged to explore their personal needs
and values and work through ways to align their behavior
and strengthen the corresponding life areas. Participants are
encouraged to formulate individual treatment goals, thereby
intending to strengthen motivation. The goals are to be realistic
and concrete and can be modified throughout the training.
Treatment success, progress difficulties, and individual coping
strategies theymight face can be documented in the activity diary.
Behavioral Activation: Overcoming Difficulties and
Pleasant Activity Scheduling (Session 2)
The second session provides strategies to overcome difficulties
concerning the active implementation of planned activities and
offers input on how to reduce avoidant behaviors related to non-
implementation of homework. As activities to restore congruence
from session 1 might not be self-rewarding in the short-term,
the second session also focuses on rather short-term mood-
enhancing activities. Participants are encouraged to plan such
individually chosen activities for the following week.
Psychoeducation (Session 3)
Psychoeducational information on depression and anxiety is
provided, and factors of etiology and maintenance are explained.
To deepen understanding of depression and anxiety, influencing
factors, risk factors, and factors of upkeep are presented. There
is a short excurse on antidepressants. After a general overview,
participants can choose throughout the session whether they
would like to receive more detailed information on depression,
anxiety, or both. Participants are encouraged to explore their
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previous and current symptom history, and describe the course
of their symptomology.
Cognitive Restructuring (Session 4)
Participants are educated on the causal relationship between
cognitions, emotions, and behavior. A thought protocol is
introduced which is divided into three components: situations,
thoughts, and consequences. Participants can individualize their
personal thought protocols by including personal situations,
cognitions, and emotions. The second phase of the thought
protocol contains questioning the reality basis of negative
thoughts, and intends for participants to identify positive and
helpful thoughts and to generally concentrate on and practice
positive thinking habits.
Problem Solving or Exposure (Session 5−6)
At this stage in the training, participants can choose whether they
would like to work on either problem solving or practice exposure
to fear-inducing situations. In problem solving participants are
educated on the distinction between solvable and unsolvable
problems and they are supposed to assign their individual
problems to these two categories. Following this is the concept
of a 6-step problem-solving plan in which they (a) identify an
individual problem, (b) define a realistic target state, (c) explore
possible solutions and decide on the most promising, (d) set up
a detailed solution plan, (e) execute the plan, and (f) verify the
implementation process. Participants are encouraged to practice
their plan the following week in real life situations. They evaluate
the success or failure of the plan in the following session and can
then opt to modify their plan accordingly.
Participants focusing on reducing their anxieties learn about
avoidant and safety behavior, the concept of habituation through
frequent confrontation of fear, and at the end of the session
participants should practice what they have learned in theory, and
expose themselves to fear-inducing situations. The mechanisms
of exposure are explained in detail, highlighting the physical
and psychological processes, with an emphasis placed upon the
effectiveness of this strategy in the long run for overall well-
being compared to avoidant strategies. Participants are requested
to identify individual difficult or fear-inducing situations in an
anxiety hierarchy. They are advised to start with their least
fearful situations and to increase intensity by enhancing practice.
In a challenge management protocol, participants can practice
exposure in a theoretical mindset. In the next session, they
evaluate the success of the implementation of their plan. They
can also identify personal safety behavior and are prepared to
focus on a more challenging situation which they are supposed
to practice the following weeks.
Plan for the Future (Session 7)
Participants see brief content summaries in the 7th session and
are asked to review the progress they have made concerning
individual training goals. Participants are instructed to identify
training mechanisms and strategies which helped them in
reducing symptoms of depression and anxiety. They are able to
write a personal letter addressed to themselves in which they
assume they have completed four more weeks of practicing newly
acquired strategies and can set goals for the coming 4 weeks.
Booster Session (Session 8)
In the booster session, which participants receive 4 weeks after
completion of the 7th session, participants can reflect on their
learning experience and individual goal attainment. They are
encouraged to explore their current state of mental health and
receive additional resources on support if needed. They are also
able to review the letter to themselves, can reassess their goals
and are instructed to make plans to implement their intentions
and actions in the following months.
Guidance and Adherence Monitoring
eCoaches support the participants throughout the training by
providing content focused guidance and adherence reminders.
Guidance can be a beneficial factor of internet interventions
(51) and can have a positive effect on treatment adherence
(52). eCoaches are psychologists or psychotherapists in training,
licensed psychotherapists or trained masters’ level psychology
students. eCoaches communicate with the participants via the
messaging function on the platform. The main role of the eCoach
is to motivate, guide participants, and monitor adherence to
the treatment as well as risk for deterioration, crisis, or other
adverse effects. Within 48 h of module completion, participants
receive written feedback on each completed module. Feedback
is based on a standardized eCoaching manual which contains
preformulated standardized text blocks prepared for each session.
The feedback will be individualized for each participant and
each module. As adherence is monitored, if participants fail to
complete a module within 7 days (14, 21 days) they will receive
individualized reminder messages by the eCoach. After 28 days
reminders will be sent via text message.
Assessments
Clinician-based and self-report assessments will take place at
screening (T0), baseline (T1), post-assessment 8 weeks after
randomization (T2), 6-month follow-up (T3), and 12-month
follow-up in the IC group (T4). There will also be weekly mood
assessments during the first seven weeks of the study phase. See
Figure 1 for a detailed overview of the study flow and Table 2
for an overview of all assessments. Clinician-based diagnostic
assessments will be conducted via telephone.
Adherence to assessments completion will be monitored
throughout the study. In case of noncompliance, study
participants will be contacted after 7 (14, 21) days to remind them
of assessment completion. After 28 days short messages will be
sent via mobile phone.
Primary Outcome
The primary outcomewill be clinician-based ratings of depressive
symptom severity at post-assessment (T2). Clinician-rated
depressive symptom severity will be assessed by the QIDS-
C (53) which covers nine criteria with 16 items: sleep, sad
mood, appetite/weight, concentration/decisionmaking, self view,
thoughts of death or suicide, general interest, energy level, and
restlessness/agitation. The items are each rated from 0 to 3. A
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TABLE 2 | Overview of self-report assessments.
Construct Questionnaire T0 T1 T2 T3
Demographics Socio-demographic data (SozDemo) X – – –
PSYCHOPATHOLOGY
Depression Center for Epidemiological Studies Depression Scale—Short
Version (CES-D)*
X X X X
Anxiety General Anxiety Disorder Measurement (GAD-7)* X X X X
Depression Patient Health Questionnaire (PHQ-9) – X – –
Alcohol abuse The Alcohol Use Disorders Identification Test (AUDIT-C) – X X X
QUALITY OF LIFE
EuroQol (EQ-5D) – X X X
Assessment Quality of Life (AQoL-8D) – X X X
RESOURCE USAGE
Client Service Receipt Inventory (CSRI) – X – X
TRAINING
Expectancy Credibility Expectancy Questionnaire (CEQ) – X – –
Negative treatment effects Inventory to assess negative effects of psychotherapy (INEP) – – X –
Program evaluation Client Satisfaction Questionnaire (CSQ-8) – – X –
OTHER
Moderators of treatment outcome Risk Factor Questionnaire (RFQ) – X – –
Worry Penn State Worry Questionnaire—Ultra Brief (PSWQ-3) – X X X
Sleep One item of Pittsburgh Sleep Quality Index (PSQI) – X X X
Emotion regulation Subscales of emotion regulation scale questionnaire (SEK−15) – X – –
Incongruence Incongruence questionnaire—short version (INK-K) – X X X
Personality Big Five Inventory (BFI-10) – X – –
Behavioral activation The Behavioral Activation for Depression Scale (BADS-FS−9) – X X X
Intervention drop-out reasons Drop-Out Reasons (DG) – – X –
Other help Other help (INH) – – X –
T0, screening; T1, baseline; T2, post-assessment; T3, 6-month follow-up.
*CES-D and GAD-7 assessed weekly until post-assessment.
meta-analysis found Cronbach’s alpha to be acceptable to good
(α = 0.69 − 0.89) (54). Trained psychologists’ who are blind
to treatment condition will conduct the diagnostic interviews.
Interrater reliability will be examined by rating interviews a
second time of ∼10% of participants by a second rater. Several
measures will be taken to ensure blinding: (1) explaining to
the participant the importance of keeping the interviewers
blinded to randomization status, (2) verbal reminder before each
assessment, (3) documentation after each assessment whether the
assessor is still blind to study condition.
Secondary Outcomes
Psychopathology
Secondary outcome measures include a clinician-based change
in diagnostic status (depression and anxiety), clinician-rated
symptom severity of anxiety, and self-report symptom severity
of anxiety and depression, the number of participants that
responded and in remission, substance use, sleep quality, quality
of life, and others.
Diagnostic status will be assessed at baseline, post-assessment,
6-month follow-up and 12-month follow-up (only in the IC) by
sections of the MINI covering depression and anxiety (social
phobia, generalized anxiety disorder, panic, agoraphobia) (48).
Self-reported depression symptom severity referring to the
previous week will be assessed by the Center for Epidemiological
Studies Depression Scale (CES-D; 20 items, item range 0–3;
reliability α = 0.95) (55, 56). The Patient Health Questionnaire
(PHQ-9; 9 items; item range 0–3; reliability α = 0.89) (57–61).
The SIGH-A, a clinician-based anxiety rating, is used to assess
anxiety severity (SIGH-A; 14 items; 0–4; reliability α = 0.89)
(62). Anxiety is also measured in self-report by the generalized
anxiety disorder measurement (GAD-7; 7 items; item range 0–3)
(61).
To evaluate response and remission rates, participants will
be coded as responders when they demonstrate a symptom
reduction of 50% assessed by CES-D or GAD-7 respectively.
Remission is defined a priori as a non-pathological score of ≤6
for the QIDS-C (53).
Other measures included alcohol consumption use (AUDIT-
C; 3 item; item range 0–4 reliability α = 0.61) (63, 64),
worrying (PSWQ-3; 3 items; item range 0–6; α = 0.85) (65, 66),
sleep quality (PSQI; 1 item; item range 1–4; α = 0.74) (67,
68), behavioral activation (BADS-FS; 9 items; item range 1–6;
α = 0.73) (69–71), and quality of life [AQoL-8D; 35 items; item
range1–5; α = [0.69–0.90] (72); EQ-5D-5L; 5 items plus 1 scale;
item range 1–5; α= [0.51–0.96] (73–75)].
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Weekly mood assessments
Depressive and anxiety symptoms will be measured weekly with
the CES-D andGAD-7 from baseline (week 1) to post-assessment
(week 8). This allows a temporally more precise assessment of
mood rating of the IC group compared to the WLC during the
intervention phase.
Training acceptability and adherence
User satisfaction with the training will be assessed after the
intervention phase using the Client Satisfaction Questionnaire
(CSQ-8; 8 items; item range 1–4; reliability α= 0.91) (76) adapted
to the online context (77). Other assessments related to the
training include the credibility expectancy questionnaire (CEQ)
(78, 79), and a questionnaire on negative effects of online training
(adaption of Inventar zur Erfassung Negativer Effekte von
Psychotherapie—INEP) (80). Adherence to session completion is
tracked throughout the intervention by the training platform.
Resource usage
To assess the impact of the intervention on publicly-funded
services and the wider society, individuals’ use of services, and
societal impacts such as productivity loss will be gathered by the
Client Service Receipt Inventory (CSRI) adapted to the German
and Swiss Health Care System (81).
Predictors and Moderators of Disorder Course and
Treatment Outcome
Predictors and moderators of treatment outcome and factors
associated with the development and maintenance of MDD and
anxiety will be assessed at baseline. These are based on a recent
review of factors such as symptoms and other easily-assessed
clinical features predicting long term treatment outcome inMDD
(47), as well as a literature search [search terms in PubMed in
June 2016: “risk factor” AND (“depression” OR “anxiety”)] on
factors predicting onset or maintenance of MDD. Predictors and
moderators of treatment outcome could help explain treatment
heterogeneity (47). Predictors and moderators will be assessed
in the demographic questionnaire, through the aforementioned
clinical assessment instruments, and in a risk factor questionnaire
(RFQ).
Demographic information
A demographic questionnaire will, among other
sociodemographic information, assess age, gender, education,
migration status, height, weight, ethnicity, current job
situation, size of household, income, sexual orientation,
and religiosity/spirituality.
Mental health
Additional mental health assessments will include 16 items from
validated instruments, and cover perceived stress (82), anxiety
sensitivity, (83), need for affect (84), worry (65), resilience (85),
energy levels, and suicide attempts.
Stressful life events and trauma
Stressful childhood and lifetime events will be assessed
by approximately 38 items using the Childhood Trauma
Questionnaire (86), family pathology and suicidality, experiences
of abuse, accident involvement, experiences of discrimination,
the List of Threatening Life events (87), and job satisfaction.
Lifestyle
Lifestyle will be assessed by the Simple Physical Activity Scale
(SIMPAQ) (88) which assesses hours of sleep, physical activity,
exercise, and sedentary behavior in the previous week as well as
subjective diet quality, diet satisfaction, smoking, and drug usage
habits.
Self-image
Aspects of self-image will be covered by 17 items, including
two on self-esteem (89), body satisfaction assessed by the Eating
Disorder Examination (90), and perceived social and minority
status.
Relationship satisfaction and loneliness
Relationship satisfaction will be assessed by the 10 item short
version of the relationship satisfaction questionnaire (91), and
loneliness will be assessed by the three item scale (92).
Other assessments
Other assessments will include subjective sleep quality assessed
by the Pittsburgh Sleep Quality Index (PSQI) (93), chronic
medical conditions, the five items of the Sense of Mastery
questionnaire (94), 23 item short version of the incongruence
questionnaire (95), the assessment of behavioral activation
(BADS-FS) (70), the ultra-short version of the Big Five
Inventory (BFI-10) (96), and various emotion regulation skill
scales (subscales comprehension, acceptance, and emotional self-
support by the German Emotion Regulation Scale Questionnaire,
ERSQ-27, ERSQ-ES-GD) (97, 98).
Statistical Analyses
Statistical analyses will be reported in accordance with the
statement by Consolidated Standards of Reporting Trials
(CONSORT) (99).
Clinical Analyses
Data analysis will be performed on an intention-to-treat
(ITT) basis. Additionally, per protocol analysis including only
participants who have completed the primary outcome will be
analyzed. Missing data will be handled by multiple imputations
(MI) with 100 iterative estimations per value, as this is currently
regarded as the gold standard with regard to missing data
(100). Demographic variables as well as other baseline variables
will be inserted into the prediction model to estimate missing
values. Differences in the primary and secondary outcomes
between the two study groups will be examined with repeated
measurements analysis of variance, and standardized effect sizes
(Cohen’s d) and number needed to treat (NNT) and their
respective confidence intervals will be calculated for comparison.
Response and remission rates will be compared across groups
with contingency tables and differences tested with χ2. All
unidirectional hypotheses will be tested one-sided, bidirectional
hypotheses will be tested two-sided. Alpha is set to p < 0.05. All
analyses will be conducted with SPSS.
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Power and Sample Size Calculation
We expect superiority of the IC compared to the WLC in the
primary outcome, clinician-based depression symptom severity
at post-assessment. The most recent systematic review on
internet-based interventions for MDD found a standardized
mean difference of g = −0.90, 95% CI −1.07 to −0.73 between
the ICs compared to untreated controls (27). We based the
sample size calculation on the lower bound of the 95% confidence
interval. To demonstrate standardized effect sizes, Cohens d, of
0.73 with a power (1 – β) of 80% and an alpha of 0.05 in a
one-sided test (calculated using G∗Power) 48 individuals would
need to be included in total (24 per group). As we aim to also
explore moderators of treatment outcome, and as simulation
studies show that the sample size required to detect an interaction
effect of the same magnitude as in the primary analysis needs
to be about three to fourfold (101), we will include N = 200
participants. This sample allows to detect effect sizes of d = 0.35
in the primary endpoint analysis.
Predictor and Moderator Analyses
Predictors and moderators of treatment outcome will be
analyzed on an exploratory basis with a priori defined
potential moderators: sociodemographic factors such as
gender, age, income, education, ethnicity, socioeconomic status,
education level, status of employment, relationship status, sexual
orientation, religious, and spiritual orientation, current and
previous mental health including age of MDD onset, MDD
severity, low energy, number of previous episodes, duration
of episodes, MDD chronicity, concurrent antidepressant
use, current/past suicidality, suicide attempts, comorbid
anxiety, anxiety sensitivity, substance use, perceived stress,
insomnia/sleep problems, rumination, need for affect, sense
of mastery, self-esteem, resilience, self-regulation, quality of
life, experience with psychotherapy, physical health including
diet, weight, body mass index, body satisfaction, number of
medical conditions, physical functioning, sedentary behavior,
smoking, drug use, quality of life, life events including childhood
maltreatment/trauma, and life events, minority, and perceived
social status, discrimination, experience of abuse, parental
and familial psychopathology, social environment, social
support/relationships, relationship satisfaction, loneliness,
personality traits such as neuroticism and openness to
experiences, and psychological coping skills such as emotion
regulation skills. Regression analyses will be used to test
interaction effects between baseline moderators and the
intervention condition, using the SPSS macro PROCESS (102).
Significant interactions will further be investigated applying the
Johnson-Neyman technique to detect the region of significance
(103).
Health Economic Evaluation
The health economic evaluation will be based on a combination
of cost-effectiveness analyses (CEA) and cost-utility analyses
(CUA). It will be conducted from a societal perspective
including all relevant costs and a public health care perspective
including only direct medical costs in a time frame of 6
months. The incremental cost-effectiveness ratio (ICER) in
the CEA is expressed by the incremental costs per additional
disorder free participant. The ICER in the CUA is expressed
as incremental costs per quality-adjusted life years gained
(QALY) based on the AQOL-8D. To test the robustness of
the ICERs and to quantify uncertainty around the ICER,
bootstrapping (5,000 times) will be used. The results will be
plotted on a cost-effectiveness plane where the horizontal axis
reflects differences in effects and the vertical axis differences
in costs, and in a cost-effective acceptability curve disclosing
the probability that the intervention is cost-effective for a
range of willingness-to-pay ceilings. The robustness of the
base-case findings will be tested by a multi-way-sensitivity
analysis.
DISCUSSION
Even though depression and anxiety are highly comorbid, they
are generally not treated by transdiagnostic treatments protocols.
With the present study, we aim to provide evidence on the
efficacy and cost-effectiveness of an internet- and mobile-based
transdiagnostic treatment for depression and comorbid anxiety
disorder and aim to explore for whom such treatments might be
suitable and for whom not.
To best assess depressive symptoms at baseline and follow-
ups, we will have diagnostic interviews and self-report which
is highly recommended (104). To minimize potential bias
in the clinical interviews we have taken precautions to
ensure blinding of outcome assessors at all assessment
times. As transdiagnostic treatment protocols are scarce
and studies are needed to further evidence-base of the treatment
potential, the study is based on a new conceptualization and
integrates transdiagnostic elements targeted at depression
and anxiety and combines this with individual participant
tailoring offering the participants individualization options
throughout the training. This method has the potential
to heighten engagement, as individuals must continuously
make active choices but also has the potential to heighten
efficacy, as individuals choose content based on personal
need.
This study also has a number of limitations. First, to
not overburden the study participants we did not assess
mediators. Hence, this study won’t provide information about
relevant mechanisms of change, which should be tested in
future studies. Second, in this study we will employ an open
recruitment strategy mimicking a public mental health approach,
in which participants self-select to participate which can be
considered a selection bias. Individuals who are familiar with
the utilization of technology and the Internet will be more
likely to participate (105). The results will therefore only
be applicable to individuals suffering from an MDD who
willingly choose to participate in internet-based treatment to
improve their mood and reduce depressive symptoms. Third,
although there was some involvement of individuals in the
intervention development phase, the extent was limited and
should be addressed more systematically and intensely in
future studies (106). Fourth, although the study is powered
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for moderation analyses, it will not be stratified for extreme
values on assessed moderator variables. Hence, it is possible
that some observations on investigated moderators, e.g., very
high chronicity of depression, will not sufficiently be included
to detect an existing effect. And lastly, although this is one
of a few studies initially powered to detect the interaction
effect between a moderator and the treatment, the sample
size still only allows to detect moderator effects in size range
of medium to large even though smaller effects could also
be of clinical interest. However, including a wide range of
potential moderators determined through an extensive literature
review can be a basis for future individual patient data meta-
analyses, which are often at a disadvantage as primary trials
commonly do not include relevant moderator variables (107,
108). Trial results will be published in a relevant peer-review
journal.
Overall, to enhance evidence-based treatment options for
comorbid disorders, more RCTs evaluating transdiagnostic
treatments are needed. Transdiagnostic tailored treatments
delivered online bear great potential to tackle the issue of
comorbidities. This study will continue to build evidence for
transdiagnostic treatment protocols, and might shed some light
on the question for whom such treatments are suitable.
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